Formulation, Characterization & In-Vitro Study of Self Micro Emulsifying Drug Delivery System of Rivaroxaban
International Journal of Drug Delivery Technology · 01.07.2026 · 16 (60s)
DOI: 10.25258/ijddt.16.60s.41 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 01.07.2026. Verfasst von Sujit Ubale und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Poor aqueous solubility limits the oral delivery of many BCS class II drugs, contributing to low and variable bioavailability; rivaroxaban, an anticoagulant with reported oral bioavailability of ~66%, was therefore formulated as a self-microemulsifying drug delivery system (SMEDDS) to enhance solubilization and in vitro performance. Materials and Methods Apparent solubility screening by UV spectrophotometry (250 nm) identified cinnamon oil as the preferred oil (19.7 ± 0.5 mg/mL; higher than Capryol 90, oleic acid, castor oil, Capmul and Captex), Cremophor EL as surfactant (12.5 ± 0.50 mg/mL), and Transcutol HP as co-surfactant (15.3 ± 0.35 mg/mL). Pseudo-ternary phase diagrams constructed by water titration at room temperature (oil:Smix 9:1 to 1:9) delineated microemulsion regions and supported selection of cinnamon oil/Cremophor EL/Transcutol HP systems. Liquid SMEDDS containing 20 mg rivaroxaban were prepared by cyclomixing and mild heating (40 °C) to obtain clear, stable preconcentrates and were evaluated for selfemulsification, dispersibility, transmittance, drug loading, compatibility, robustness, thermodynamic stability, and droplet characteristics.
Results
Formulations emulsified rapidly (≈20–30 s; 95% transmittance (e.g., 98.3 ± 0.71% in water) and drug loading was high (e.g., 98.14 ± 0.78%). FT-IR peaks of the formulation matched pure rivaroxaban, indicating no detectable drug–excipient interaction, and samples passed centrifugation (3500 rpm, 30 min) and freeze–thaw cycling (−20 to +25 °C). Droplet sizes across oil:Smix ratios were in the ~198–257 nm range with negative zeta potential, while the optimized F1 1:9 system showed ~257 nm droplets, PDI ~0.63, and zeta potential around −17.2 mV. In 0.1 N HCl, the SMEDDS markedly accelerated dissolution versus a marketed tablet supporting SMEDDS as a promising approach to improve rivaroxaban delivery and, more broadly, oral performance of poorly water-soluble drugs.
Conclusion
The developed SMEDDS formulation of rivaroxaban demonstrated excellent self-emulsification properties, rapid drug release, and enhanced dissolution compared to conventional marketed tablets. This approach offers a promising strategy for improving the oral bioavailability of BCS class II drugs like rivaroxaban.
Zitieren
APA
Ubale, S., & Singh, R. P. (2026). Formulation, Characterization & In-Vitro Study of Self Micro Emulsifying Drug Delivery System of Rivaroxaban. International Journal of Drug Delivery Technology, 16(60s). https://doi.org/10.25258/ijddt.16.60s.41
Vancouver
Ubale S, Singh RP. Formulation, Characterization & In-Vitro Study of Self Micro Emulsifying Drug Delivery System of Rivaroxaban. International Journal of Drug Delivery Technology. 2026;16(60s). doi:10.25258/ijddt.16.60s.41
BibTeX
@article{Ubale2026,
author = {Ubale, Sujit and Singh, R. P.},
title = {Formulation, Characterization & In-Vitro Study of Self Micro Emulsifying Drug Delivery System of Rivaroxaban},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {60s},
doi = {10.25258/ijddt.16.60s.41}
}
EUVIMED